DEPDC5 and tuberous sclerosis: Similarly, clinical justification for off-label treatment with everolimus in severe DEPDC5-related DRE is supported by favourable safety and tolerability data from TSC studies,12 and reports of rapamycin-responsive seizures in rodent models of Depdc5 knockout.55